RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...

Some drugs can activate AMPK, most prominently metformin, which is approved for diabetes and being trialed in dementia. Less well-known is aldometanib, developed by Lin’s team, which blocks aldolase, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Researchers have found that polyphenols cause the secretion of hormones that may help lower a risk of developing type 2 ...

More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...